Kiin Bio secures €1.9 million in Pre-Seed funding led by b2venture to enhance its AI-powered drug discovery platform.
Kiin Bio secures €1.9 million in Pre-Seed funding led by b2venture to enhance its AI-powered drug discovery platform.
06/08/25, 4:16 PM
Location
londonMoney raised
€1.9 million
Industry
machine learning
artificial intelligence
biotechnology
Round Type
seed
Investors
Rule30, Heartfelt, B2venture
Kiin Bio has successfully raised €1.9 million in an oversubscribed pre-Seed funding round. The round was led by b2venture with participation from Heartfelt, rule30, and several strategic angel investors. This investment will fuel Kiin Bio’s growth and enhance its AI capabilities. The company aims to revolutionize the drug discovery process with its innovative Virtual Scientist Platform, KiinOS.
Company Info
Location
london, england, united kingdom
Additional Info
Kiin Bio is a London-based life sciences startup focused on revolutionizing the drug discovery process through their AI-powered Virtual Scientist Platform, KiinOS. This innovative platform integrates various tools and data sources to streamline research from literature review to wet-lab execution. Kiin Bio's AI-native approach addresses the challenges of fragmented and costly drug discovery, aiming to accelerate research and innovation in the pharmaceutical industry. With several pilot projects and partnerships already underway, the company is positioned for significant growth.